Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Context Therapeutics (CNTX) · oqro.io/stocks/CNTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Context Therapeutics insider trading
Have Context Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Context Therapeutics was filed in the last 90 days. The latest on record was on Jun 10, 2025.
How often do Context Therapeutics insiders buy and sell shares?
Since 2021, Context Therapeutics insiders reported 18 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2025.
Who is selling Context Therapeutics stock?
No open-market sale by an insider of Context Therapeutics (CNTX) was filed with the SEC in the last 90 days.
Do members of Congress trade CNTX?
No trade in Context Therapeutics (CNTX) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−86.0% (−$0.98) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.14 on Nov 20, 2025 to $0.16 on Nov 20, 2026 (−86.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$-1$1$2$3$4$0.16
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Philadelphia, Pa.
Last 12 months
−86.0%
S&P 500 +5.7% over the same dates
Market value
$15.7M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 4.7M shares sold short (4.8% of shares outstanding), +9.9% vs the previous count, 3.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
—
Free cash flow, last 12 months
−$34M
This quarter −$6.58M, a year earlier −$6.58M
Net debt
—
Debt —, cash $34.4M, at Sep 30, 2026
Net income, last 12 months
−$43.9M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Mar 22, 2023.
The CEO of Context Therapeutics paid $70K out of pocket for Context Therapeutics shares. 2 other people at Context Therapeutics bought some too, in the same month. Shares held went up 12% with this purchase.
The CFO of Context Therapeutics paid $25K out of pocket for Context Therapeutics shares. 2 other people at Context Therapeutics bought some too, in the same month. Shares held went up 100% with this purchase.
Context Therapeutics's Chief Legal Officer, Corp. Sec paid $12K out of pocket for Context Therapeutics shares. 2 other people at Context Therapeutics bought some too, in the same month. Shares held went up 222% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Red flags in its filings
Jul 31
Notice of delisting or failure to meet listing rules
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insider buying and selling since 2021
Insiders of Context Therapeutics reported 18 open-market purchases and 0 sales since 2021; purchases in 4 different years, most recently 2025.
Year
Bought
Sold
2025
$107K3×3 trades
—
2023
$30K6×6 trades
—
2022
$109K6×6 trades
—
2021
$107K3×3 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
From “Overview”, in the company's words
We are a clinical-stage biopharmaceutical company advancing TCE bispecific antibodies for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a CLDN6 x CD3 TCE, CT-95, an MSLN x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. CTIM-76 is a CLDN6 x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. We have an active IND for CTIM-76 with the FDA. We dosed the first patient in our CTIM-76 Phase 1 clinical trial in January 2025. We expect to share Phase 1a interim data for the CTIM-76 trial in June 2026.
What the section covers (27 headings)
Overview
Asset Acquisition Agreements
CTIM-76: Integral Molecular License Agreement
CT-95: Link Purchase Agreement
CT-202: BioAtla License Agreement
Financial Overview
At-the-Market Offering
Private Placement
Components of Our Results of Operations
Operating Expenses
Research and Development Expenses
General and Administrative Expenses
Interest Income
Other Income (Expense)
And 13 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 23, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Context Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 3 open-market purchases (about $107K, in 3 filings) and 0 open-market sales (about $0, in 0 filings). (Context Therapeutics on OQRO)
Contracts, lobbying and filings. FINRA short interest for CNTX on the settlement date of Oct 30, 2026 was 4,695,883 shares (+9.9% on the previous report), about 3.68 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Omers Administration Corp (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Context Therapeutics filed a Form 8-K on Jul 31, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange. The company's own opening sentence of that report reads: "On July 29, 2026, Context Therapeutics Inc. (the 'Company') received written notice (the 'Notification Letter') from the Nasdaq Listing Qualifications Department (the 'Staff') of The Nasdaq Stock Market LLC ('Nasdaq') stating tha..."
Who holds it. 79 funds reported a stake in Context Therapeutics in their 13F for Q2 2026. The largest by value: Nextech Invest Ltd. (11.8% of the value reported), Deep Track Capital, LP (11.8% of the value reported), Soleus Capital Management, L.P. (11.3% of the value reported).
Off-exchange trading: 58.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (15.9% on ATS, 42.6% with other brokers), close to its 26-week average of 58.0%. Weeks of Sep 21 to Oct 16, 2026.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Context Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 3 open-market purchases (about $107K, in 3 filings) and 0 open-market sales (about $0, in 0 filings).
Contracts, lobbying and filings
FINRA short interest for CNTX on the settlement date of Oct 30, 2026 was 4,695,883 shares (+9.9% on the previous report), about 3.68 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: none on record; the largest that shrank: Omers Administration Corp (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Context Therapeutics filed a Form 8-K on Jul 31, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
The company's own opening sentence of that report reads: "On July 29, 2026, Context Therapeutics Inc. (the 'Company') received written notice (the 'Notification Letter') from the Nasdaq Listing Qualifications Department (the 'Staff') of The Nasdaq Stock Market LLC ('Nasdaq') stating tha..."
Context Therapeutics filed a Form 8-K on Jun 26, 2026 (Items 5.03, 5.07) that OQRO classes as: changed its bylaws, charter or fiscal year, and held a shareholder vote.
Context Therapeutics filed a Form 8-K on May 18, 2026 (Items 1.01, 7.01) that OQRO classes as: signed an important agreement, and shared information with investors.
CNTX closed at $0.1664 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $0.2384 to $0.1664, a change of −30.2%.
Who holds it
79 funds reported a stake in Context Therapeutics in their 13F for Q2 2026. The largest by value: Nextech Invest Ltd. (11.8% of the value reported), Deep Track Capital, LP (11.8% of the value reported), Soleus Capital Management, L.P. (11.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (16.6%), ONECHRONOS (15.9%), IBKR ATS (12.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Owners above 5%
No Schedule 13D or 13G filing on CNTX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Risk factors in the annual report
Latest annual report filed Mar 23, 2026, compared with the one filed Mar 20, 2025. Read the filing
New risk factors in the latest annual report (5 headings)
Changes in U.S. trade policy, including the imposition of tariffs and the resulting consequences, may have a material adverse impact on our business, financial condition, and results of operations.
We may be required by the FDA to obtain approval of a companion diagnostic in connection with approval of our current product candidates, and if we do not obtain, or face delays in obtaining, FDA approval of such companion diagnostic, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired.
Fast track designation from the FDA may not actually lead to a faster development or regulatory review or approval process.
We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.
Changes to United States federal regulatory agencies may cause disruptions and delays in government approval processes and regulations relating to our product candidates.
No longer listed (3 headings from the year before)
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline.
We do not expect to pay dividends in the foreseeable future, and you must rely on price appreciation of your shares for return on your investment.
We may issue debt and equity securities, which are senior to our common stock as to distributions and in liquidation, which could materially adversely affect the market price of our common stock.
Legal proceedings (Item 3)
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Except as disclosed below, we are not presently a party to any material legal proceedings. On February 4, 2026, the Vladimir Gusinsky Revocable Trust filed a stockholder class action complaint (the “Action”) against us and our directors in the Court of Chancery of the State of Delaware (the “Court”) asserting that (i) Article V, Section 2 of our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), provides for a full term of three years…
Source: SEC EDGAR, Form 10-K filed Mar 23, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.